FDA Clears Tarsus’ Xdemvy as First Treatment for Common Eyelid Disease
July 27, 2023
Source: drugdu
112
Patients with the eyelid disease Demodex blepharitis can now see a cure in Tarsus Pharmaceuticals’ Xdemvy, the first FDA-approved treatment for an ailment that affects some 25 million Americans.
The eye drops directly target Demodex mites, an ectoparasite infestation that causes the disease.
Tarsus expects Xdemvy, an eye drop formulation of pet flea and tick treatment lotilaner, to be available by the end of August. The company has already started marketing for the often-misdiagnosed disease with a campaign called “Don’t Freak Out. Get Checked Out," which launched in May.
And last year, the company started a marketing campaign called “Look at the Lids,” which encourages eye doctors to screen for the condition.
In two trials involving more than 833 patients, investigators testing the drug noted improvement in collarettes, which is the accumulation of the mite’s waste and eggs.
Before Xdemvy, the 1 in every 12 U.S. adults who suffer from the condition turned to tea tree oil and lid wipes, which don’t target the root cause of the disease.
Elsewhere, the company’s pipeline includes treatments for meibomian gland dysfunction, rosacea and Lyme disease.
Source: ophthalmologyTimes.com
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Chuangxiang Biotechnology and Ikena Oncology merge to raise $75 million in funding December 25, 2024
- Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved December 25, 2024
- ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical December 25, 2024
- CR Group’s Big Move – Integration of Two Major Pharmaceutical Companies Completed December 25, 2024
- CanSino Biologics Launches Phase I/II Clinical Trials for Recombinant Polio Vaccine December 25, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
